August Generoso1, Christine Muglia-Chopra1, John Oppenheimer2. 1. Rutgers New Jersey Medical School, The State University of New Jersey, 90 Bergen Street, Newark, NJ, 07103, USA. 2. Rutgers New Jersey Medical School, The State University of New Jersey, 90 Bergen Street, Newark, NJ, 07103, USA. nallopp22@gmail.com.
Abstract
PURPOSE OF REVIEW: The profile of biologic therapies for asthma is growing rapidly. We discuss how to match the proper pediatric patient with the most effective therapy. RECENT FINDINGS: Currently available biologic therapies are most effective in patients with T2 high asthma. Newer drugs are currently being studied which target TSLP and interleukin 33. These newer drugs may provide options for asthmatics who do not respond to the current anti-IgE, anti-IL5, and anti-IL4/13 therapies. Asthma is a heterogeneous disease which can be driven by different inflammatory mediators in different patients. To select the most effective biologic therapy for a pediatric patient, the asthma phenotype must first be determined. The steep cost of biologics limits their use, which makes proper pairing of patient to therapy even more crucial. Presently, several therapies exist for T2 high asthma, but it is hoped in the future that development of drugs effective for T2 low asthmatics will be available as well.
PURPOSE OF REVIEW: The profile of biologic therapies for asthma is growing rapidly. We discuss how to match the proper pediatric patient with the most effective therapy. RECENT FINDINGS: Currently available biologic therapies are most effective in patients with T2 high asthma. Newer drugs are currently being studied which target TSLP and interleukin 33. These newer drugs may provide options for asthmatics who do not respond to the current anti-IgE, anti-IL5, and anti-IL4/13 therapies. Asthma is a heterogeneous disease which can be driven by different inflammatory mediators in different patients. To select the most effective biologic therapy for a pediatric patient, the asthma phenotype must first be determined. The steep cost of biologics limits their use, which makes proper pairing of patient to therapy even more crucial. Presently, several therapies exist for T2 high asthma, but it is hoped in the future that development of drugs effective for T2 low asthmatics will be available as well.
Entities:
Keywords:
Asthma; Biologic therapy; Children; Pediatrics; T2 high
Authors: Eugene R Bleecker; J Mark FitzGerald; Pascal Chanez; Alberto Papi; Steven F Weinstein; Peter Barker; Stephanie Sproule; Geoffrey Gilmartin; Magnus Aurivillius; Viktoria Werkström; Mitchell Goldman Journal: Lancet Date: 2016-09-05 Impact factor: 79.321
Authors: Michael S Blaiss; Mario Castro; Bradley E Chipps; Myron Zitt; Reynold A Panettieri; Michael B Foggs Journal: Ann Allergy Asthma Immunol Date: 2017-11-02 Impact factor: 6.347
Authors: B Popovic; J Breed; D G Rees; M J Gardener; L M K Vinall; B Kemp; J Spooner; J Keen; R Minter; F Uddin; G Colice; T Wilkinson; T Vaughan; R D May Journal: J Mol Biol Date: 2016-12-09 Impact factor: 5.469
Authors: Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord Journal: N Engl J Med Date: 2014-09-08 Impact factor: 91.245